Published in Drug Resist Updat on March 28, 2012
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion. Front Pharmacol (2014) 1.00
Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. Oncotarget (2015) 0.90
Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther (2013) 0.86
Membrane transporters as mediators of Cisplatin effects and side effects. Scientifica (Cairo) (2012) 0.81
Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer. Am J Cancer Res (2015) 0.79
Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells. PLoS One (2015) 0.77
Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer. Breast Cancer (Auckl) (2015) 0.76
Inhibitory effects of chemotherapeutics on human organic anion transporter hOAT4. Int J Biochem Mol Biol (2016) 0.75
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene (2003) 10.74
Targeting multidrug resistance in cancer. Nat Rev Drug Discov (2006) 10.55
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol (2006) 6.00
Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man. Br J Clin Pharmacol (1975) 5.02
Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell (2006) 4.84
Translation of the Philadelphia chromosome into therapy for CML. Blood (2008) 4.74
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst (2007) 4.07
A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst (2000) 3.98
Management of malignant gastrointestinal stromal tumours. Lancet Oncol (2002) 3.93
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res (1996) 3.77
The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch (2003) 3.76
ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res (2005) 3.52
Active transport of imatinib into and out of cells: implications for drug resistance. Blood (2004) 3.52
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A (2002) 3.28
A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A (2007) 3.15
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood (2006) 3.00
Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol (2008) 2.85
Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med (1948) 2.81
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood (2008) 2.76
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol (1996) 2.67
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer (2005) 2.54
Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther (2007) 2.52
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A (2005) 2.34
Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med (2009) 2.33
Biochemical characterization of the human copper transporter Ctr1. J Biol Chem (2001) 2.28
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol (2008) 2.26
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther (2005) 2.23
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. Proc Natl Acad Sci U S A (2001) 2.19
Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol (2009) 2.16
Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther (2002) 2.13
Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther (2009) 2.10
Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res (2004) 2.10
Tracing pathways of transport protein evolution. Mol Microbiol (2003) 2.09
Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood (2004) 2.08
Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev (2011) 2.08
High-dose methotrexate: insecure rationale: take 2. J Pediatr Hematol Oncol (2008) 2.08
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol (2010) 2.07
Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem (1968) 2.07
Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem (1998) 2.05
Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol (2007) 2.05
hCTR1: a human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci U S A (1997) 2.04
Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol (1998) 2.03
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology (2001) 2.02
Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol (2010) 1.99
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol (2002) 1.94
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther (2009) 1.94
Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov (2008) 1.93
Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J Biol Chem (2002) 1.91
Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol (1997) 1.91
Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem (1999) 1.87
Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol (2002) 1.85
Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol (1999) 1.84
Folate-mediated one-carbon metabolism. Vitam Horm (2008) 1.81
Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol (2006) 1.80
Drug excretion mediated by a new prototype of polyspecific transporter. Nature (1994) 1.77
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol (2010) 1.76
Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol (2006) 1.75
Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem (1997) 1.75
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol (2005) 1.73
The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos (2008) 1.69
Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol (2011) 1.69
cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects. Proc Natl Acad Sci U S A (2008) 1.62
Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem (1997) 1.62
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol (2011) 1.60
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain. J Pharmacol Exp Ther (2010) 1.59
Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther (2010) 1.57
The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol (2008) 1.56
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res (1983) 1.53
Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther (2006) 1.52
The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res (2006) 1.51
Expression cloning of a rat liver Na(+)-independent organic anion transporter. Proc Natl Acad Sci U S A (1994) 1.51
Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter. Cancer Biol Ther (2006) 1.50
Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest (1996) 1.49
Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res (2004) 1.49
The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol (2008) 1.48
Interaction of imatinib with human organic ion carriers. Clin Cancer Res (2008) 1.47
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther (2007) 1.47
Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med (1996) 1.47
Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res (2008) 1.46
Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos (2004) 1.45
Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res (2004) 1.42
Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer (1974) 1.42
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res (2012) 2.95
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst (2002) 2.84
Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol (2003) 2.83
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol (2002) 2.44
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. Clin Pharmacokinet (2003) 2.44
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther (2005) 2.23
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20
Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst (2002) 2.16
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood (2007) 2.15
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol (2010) 2.07
Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol (2002) 1.99
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res (2008) 1.95
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J Clin Oncol (2007) 1.92
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol (2004) 1.85
Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol (2005) 1.81
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist (2007) 1.78
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res (2010) 1.69
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol (2011) 1.60
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol (2006) 1.56
Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol (2013) 1.56
Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer (2005) 1.54
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol (2006) 1.53
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res (2008) 1.48
Interaction of imatinib with human organic ion carriers. Clin Cancer Res (2008) 1.47
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther (2007) 1.47
Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res (2008) 1.46
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Clinical pharmacokinetics of docetaxel : recent developments. Clin Pharmacokinet (2006) 1.41
Medicinal cannabis in oncology practice: still a bridge too far? J Clin Oncol (2005) 1.41
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib. Cancer Biol Ther (2007) 1.40
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res (2006) 1.40
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst (2006) 1.38
Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res (2004) 1.36
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res (2009) 1.35
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther (2005) 1.34
Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res (2008) 1.34
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther (2006) 1.33
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res (2004) 1.31
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. Expert Opin Drug Metab Toxicol (2005) 1.29
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood (2011) 1.25
Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.25
Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res (2012) 1.24
Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro (2005) 1.24
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer (2006) 1.23
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res (2002) 1.22
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res (2008) 1.22
Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. Anal Biochem (2004) 1.21
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res (2006) 1.19
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. Pharmacogenomics (2005) 1.18
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res (2004) 1.16
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res (2012) 1.15
Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.13
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res (2005) 1.13
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther (2008) 1.13
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses. Clin Cancer Res (2003) 1.12
Review of UCN-01 development: a lesson in the importance of clinical pharmacology. J Clin Pharmacol (2005) 1.12
Synthesis of apoptosis-inducing iminophosphorane organogold(III) complexes and study of their interactions with biomolecular targets. Inorg Chem (2009) 1.12
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol (2002) 1.10
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst (2004) 1.10
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.09
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs (2007) 1.09
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A (2013) 1.08
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther (2002) 1.08
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol (2004) 1.08
Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol (2005) 1.07
Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol (2010) 1.07
Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res (2010) 1.06
Relationship of systemic exposure to unbound docetaxel and neutropenia. Clin Pharmacol Ther (2005) 1.05
Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res (2004) 1.05
Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol (2002) 1.05
A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther (2005) 1.04
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist (2006) 1.03
Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol (2013) 1.02
Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res (2010) 1.01
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther Clin Risk Manag (2005) 1.01
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res (2005) 1.01
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets (2002) 1.01
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther (2003) 0.99
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther (2006) 0.99
Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2005) 0.99
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res (2013) 0.97
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther (2004) 0.97
Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat (2004) 0.97
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res (2004) 0.96
Pharmacogenomic importance of ABCG2. Pharmacogenomics (2008) 0.96
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res (2004) 0.95
Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms. Drug Metab Dispos (2008) 0.95
Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.94
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 0.92
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology (2007) 0.91
Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics (2009) 0.90
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel. Anticancer Drugs (2002) 0.90
Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br J Clin Pharmacol (2005) 0.90